From Glycemic Control to Cardiorenal Protection: Improving Outcomes With SGLT2 Inhibitors
May 15, 2021
Experts Dr. Lawrence Leiter (Chair), Dr. Jennifer Green, Dr. Javed Butler, and Dr. David Cherney from multiple specialties (endocrinology, cardiology, and nephrology) will through lecture, case presentations, and panel discussion, provide perspectives on translating evidence into clinical practice and indicate considerations for using SGLT2 inhibitors safely and effectively in patients with, and at high risk for CV disease, HF, and chronic kidney disease (CKD).
No Credit Available
New Pathways to GLYCEMIC CONTROL: Focus on the Kidney
October 28, 2014
Presentations by Jay Shubrook, DO (Chair), Eugene Cersosimo, MD, PhD, and Robert Henry, MD. discussing the role of glucose regulation and SGLT 2 inhibitors in antihyperglycemic therapy
No Credit Available